WHO adds GLP-1 drugs for diabetes, others to essential medicines list

The World Health Organization has added GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list, specifically for type 2 diabetes with cardiovascular disease, chronic kidney disease, or obesity, to improve global access to these costly treatments. This strategic inclusion, despite the drugs' high price, aims to catalyze broader availability and encourage generic production as key patents begin to expire next year, addressing the significant global burden of diabetes and obesity.

Analysis

The World Health Organization's addition of GLP-1 drugs, specifically Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list is a dual-impact event for the pharmaceutical sector. On one hand, it serves as a powerful validation of the therapies' clinical importance for type 2 diabetes with associated cardiovascular disease, chronic kidney disease, or obesity, signaling a significant long-term demand floor, particularly in emerging markets. On the other hand, the WHO's explicit goal is to catalyze global access and encourage generic competition, directly highlighting the high price points of these drugs and the impending patent expirations starting next year. This development creates a headwind of anticipated price erosion and competition, reflected in the cautious overall tone. For Merck, the inclusion of Keytruda for expanded cancer indications reinforces its market leadership and growth trajectory. Conversely, a negative sentiment is associated with Vertex Pharmaceuticals, as the inclusion of its cystic fibrosis drug is framed alongside criticism of its high price and lack of accessibility, underscoring a growing global regulatory focus on drug affordability.

Key Decisions for Investors

• For investors in Novo Nordisk and Eli Lilly, the WHO's endorsement solidifies long-term demand for GLP-1s in emerging markets, but it also elevates the risk of price pressure and accelerated generic competition, warranting close monitoring of patent expiration and pricing strategies.
• The inclusion of Merck's Keytruda for additional oncology indications is a positive catalyst that reinforces the drug's market dominance and may support sustained volume growth, strengthening its long-term value proposition.
• This action signals a broader trend of heightened global regulatory scrutiny on drug affordability, meaning investors should factor in increased pricing pressure as a key risk for companies with high-cost therapies, particularly those like Vertex that have been cited for accessibility issues.